Lipid therapy: Prevention of arteriosclerotic cardiovascular diseases;Lipidtherapie: Prävention arteriosklerotischer Herz-Kreislauf-Erkrankungen

Internist

Volumn 42, Issue 1, 2001, Pages 92-110

  Windler, E ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTERIOSCLEROSIS; BRAIN ATHEROSCLEROSIS; CARDIOVASCULAR RISK; COGNITION; FEMALE; HIGH RISK PATIENT; HUMAN; HYPERTRIGLYCERIDEMIA; MALE; MORBIDITY; MORTALITY; PRIMARY PREVENTION; PROGNOSIS; REVIEW; RISK FACTOR; SECONDARY PREVENTION;

ANTICHOLESTEREMIC AGENTS; ANTILIPEMIC AGENTS; ARTERIOSCLEROSIS; CHOLESTEROL, LDL; COMBINED MODALITY THERAPY; CORONARY ARTERIOSCLEROSIS; DIET, FAT-RESTRICTED; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; RISK FACTORS; TRIGLYCERIDES;

EID: 0035103852     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001080050728     Document Type: Review

References (68)

1. Value of electron-beam computed tomography for the noninvasive detection of high-grade coronary-artery stenosis and occlusions
2. Management of dyslipidemia in adults with diabetes
3. Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease
4. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport
5. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
6. Lipid lowering and plaque regression: New insights into prevention of plaque disruption and clinical events in coronary disease
7. The influence of pravastatin on progression and regression of coronary atherosclerosis in men with normal or mildly raised serum cholesterol. Results of the Regression Growth Evaluation Statin Study (REGRESS)
8. Effect of HMG-CoA-reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography
9. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: The Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993
10. Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations
11. 10-Year follow-up results from the Göttingen Risk Incidence and Prevalence Study (GRIPS). I. Risk factors for myocardial infarction in a cohort of 5790 men
12. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels
13. An angiographic evaluation of the effects of bezafibrate on the progression of coronary artery disease in young male post-infarction patients. The bezafibrate coronary atherosclerosis intervention trial (BECAIT)
14. Summary of the second report of the National Cholesterol Education Program (NCEP) - Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
15. Coronary plaque disruption
16. Relation of plaque lipid composition and morphology to the stability of human aortic plaques
17. Helsinki heart study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia
18. Atherosclerotic plaque rupture and thrombosis - Evolving concepts
19. The pathogenesis of coronary artery disease and the acute coronary syndromes
20. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzione trial
21. High-density lipoprotein cholesterol and cardiovascular disease - Four prospective American studies
22. Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease. A potential noninvasive marker of healing coronary endothelium
23. Studies of Japanese migrants. I. Mortality from cancer and other diseases among Japanese in the United States
24. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction
25. Five-year incidence of coronary heart disease related to major risk factors and metabolic control in newly diagnosed non-insulin-dependent diabetes - The diabetes intervention study (DIS)
26. The lipoprotein and coronary atherosclerosis study (LCAS): Lipid and metabolic factors related to atheroma and clinical events
27. Relation of coronary heart disease incidence and total mortality to plasma cholesterol reduction in randomised trials: Use of meta-analysis
28. The HOPE study. Ramipril lowered cardiovascular risk, but vitamin E did not
29. Overall and coronary heart disease mortality rates in relation to major risk factors in 325 348 men screened for the MRFIT
30. The seven countries study: 2289 Deaths in 15 years
31. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease
32. Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes
33. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?
34. Cholesterol reduction in cardiovascular disease: Clinical benefits and possible mechanisms
35. Hypertension: The coronary heart disease dilemma
36. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering
37. Lifetime risk of developing coronary heart disease
38. MRC trial of treatment of mild hypertension: Principal results
39. Can lifestyle changes reverse coronary heart disease? - The Lifestyle Heart Trial
40. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease
41. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4 S)
42. Effect of Simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4 S)
43. Simvastatin-induced reduction in risk of major coronary events is related to both reduction in LDL-cholesterol and increase in HDL-cholesterol
44. Follow-up study of patients randomized in the Scandinavian Simvastatin Survival Study (4 S) of cholesterol lowering
45. Should treatment recommendations for lipid lowering drugs be based on absolute coronary risk or risk reductions?
46. Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients
47. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
48. Ultrasonographically assessed carotid morphology and the risk of coronary heart disease
49. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4 S)
50. Hospital care and survival of acute myocardial infarction patients in Minnesota and southern Germany: A comparative study
51. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
52. Modified forms of low-density lipoprotein and atherosclerosis
53. Prevention of cardiovascular events and death with Pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
54. Coronary heart disease: Reducing the risk
55. Ist eine vitamin E-supplementierung zur prävention der korona-ren herzkrankheit sinnvoll?
56. Clinical lipidology at the end of the millenium
57. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
58. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
59. Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris
60. Coronary and cardiovascular risk estimation for primary prevention: Validation of a new Shef-field table in the 1995 Scottish health survey population
61. Nutrient intake and progression of coronary artery disease
62. Homocysteine and atherothrombosis
63. High-density lipoprotein cholesterol and other risk factors for coronary heart disease in female runners
64. Hyper- und dyslipoprote-inämien
65. Gesundheitsökonomie der behandlung von fettstoffwechselstörungen
66. Prevention of coronary heart disease in clinical practice: Recommendations of the Second Joint Task Force of European and other societies on coronary prevention
67. Coronary atherosclerotic wall thickening and vascular reactivity in humans. Elevated high-density lipoprotein levels ameliorate abnormal vasoconstriction in early atherosclerosis